Clinical trial
An Investigational Immuno-therapy Study to Evaluate Safety and Effectiveness in…
NCT02320058 · Bristol-Myers Squibb, Industry · Completed
Key facts
| NCT number | NCT02320058 |
|---|---|
| Title | An Investigational Immuno-therapy Study to Evaluate Safety and Effectiveness in Patients With Melanoma That Has Spread to the Brain, Treated With Nivolumab in Combination With Ipilimumab, Followed by Nivolumab by Itself |
| Official title | A Multi-Center Phase 2 Open-Label Study to Evaluate Safety and Efficacy in Subjects With Melanoma Metastatic to the Brain Treated With Nivolumab in Combination With Ipilimumab Followed by Nivolumab Monotherapy |
| Acronym | CheckMate204 |
| Lead sponsor | Bristol-Myers Squibb, Industry |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Melanoma |
| Intervention type | Drug |
| Interventions | Ipilimumab, Nivolumab |
| Enrollment | 119 |
| Start date | Mar 5, 2015 |
| Primary completion | Sep 8, 2020 |
| Completion | Sep 8, 2020 |
| First posted | Dec 19, 2014 |
| Last update posted | Oct 5, 2021 |
| Countries | United States |
At a glance
- 10–99 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: